Endocrine disruptors linked to PCa, cryptorchidism
February 25th 2013Many synthetic chemicals, untested for their disrupting effects on the hormone system, may have significant health implications, including contributing to the development of prostate cancer in men and undescended testes in young males.
'Field effect' markers may detect occult prostate Ca
February 25th 2013Three "field effect" epigenetic biomarkers were found to be more prevalent in histologically benign biopsy cores from prostate cancer patients diagnosed with Gleason score 7 prostate cancer than in those with low-volume Gleason 6 disease, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.
FDA grants priority review to metastatic PCa agent
February 19th 2013The FDA has granted priority review to the new drug application filed for radium-223 dichloride, an investigational compound under review for the treatment of patients with castration-resistant prostate cancer who have bone metastases.